Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VALEANT PHARMACEUTICALS INTL INC T.VRX

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."


TSX:VRX - Post by User

Post by yrmacon Jul 10, 2017 5:49pm
197 Views
Post# 26452830

results q2 aug. 8 8.00 am

results q2 aug. 8 8.00 am17:00:00 07/10/2017 LAVAL, Quebec, Jul 10, 2017 (Canada NewsWire via COMTEX News Network) -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it plans to release second quarter 2017 financial results on Tuesday, Aug. 8, 2017. The Company will host a conference call and live webcast at 8:00 a.m. EDT to discuss the results and provide a business update. All materials will be made available on the investor relations portion of the corporate website before the start of the conference call. Conference Call Details Date Tuesday, Aug. 8, 2017 Time 8:00 a.m. EDT Webcast https://ir.valeant.com/events-and-presentations Participant Event Dial-in (877) 876-8393 (North America) (443) 961-0178 (International) Participant Passcode 35736021 Replay Dial-in (855) 859-2056 (North America) (404) 537-3406 (International) Replay Passcode 31833 (replay available until Oct. 8, 2017) About Valeant Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com. Investor Contacts: Arthur Shannon Elif McDonald arthur.shannon@valeant.com elif.mcdonald@valeant.com 514-856-3855 514-856-3855 877-281-6642 (toll free) 877-281-6642 (toll free) Media Contact: Lainie Keller lainie.keller@valeant.com 908-927-0617 View original content with multimedia:https://www.prnewswire.com/news-releases/valeant-announces-q2-2017-financial-results-date-and-conference-call-details-300485451.html SOURCE Valeant Pharmaceuticals International, Inc. View original content with multimedia: https://www.newswire.ca/en/releases/archive/July2017/10/c6765.html SOURCE: Valeant Pharmaceuticals International, Inc. Copyright (C) 2017 CNW Group. All rights reserved.
<< Previous
Bullboard Posts
Next >>